首页 > 最新文献

Journal of Translational Internal Medicine最新文献

英文 中文
Selective HDAC8 inhibition by PCI-34051 attenuates inflammation and airway remodeling in asthma via miR-381-3p-TGFβ3 axis. PCI-34051选择性抑制HDAC8通过mir -381-3p- tgf - β3轴减轻哮喘炎症和气道重塑。
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-01-10 eCollection Date: 2024-12-01 DOI: 10.1515/jtim-2023-0135
Shiyao Bai, Xinming Su, Delei Kong, Chenye Feng, Xiaochun Zhang, Ying Pan, Jieyu Zhao, Jiamin Sun, Wenyang Li

Background and objectives: Histone deacetylase (HDAC) families regulate various physical processes and the development of several diseases. The role of HDACs in asthma development and progression worths further investigation. This study aims to evaluate the effect of HDACs in a mouse model of asthma.

Methods: HDAC8 selective inhibitor PCI-34051 was administered to a mouse model of ovalbumin-sensitized and challenged asthma. Airway responsiveness, serum cytokines, histological changes of the airway, and expression levels of α-SMA, β-actin, VEGFR, VEGF, GAPDH, HDAC8, TGF-β3, CD 105, p-ERK 1/2, ERK 1/2, PI3K, p-AKT, AKT, and PDK1 were evaluated. The miR-381-3p level was also measured.

Results: All classic histologic and cellular changes of asthma in inflammation and airway remodeling were altered by HDAC8 inhibitor PCI-34051 via regulation of the miR-381-3p level and its downstream gene, TGF-β3. Inhibition of TGF-β3 further reduced the activation of ERK, PI3K, AKT, and PDK1.

Conclusion: In a mouse model, HDAC8 inhibitor PCI-34051 exhibits comprehensive control of asthmatic changes, including inflammation and airway remodeling.

背景和目的:组蛋白去乙酰化酶(HDAC)家族调节多种生理过程和多种疾病的发展。hdac在哮喘发生和进展中的作用值得进一步研究。本研究旨在评价hdac在哮喘小鼠模型中的作用。方法:采用HDAC8选择性抑制剂PCI-34051治疗卵清蛋白致敏哮喘小鼠模型。评估气道反应性、血清细胞因子、气道组织学变化及α-SMA、β-actin、VEGFR、VEGF、GAPDH、HDAC8、TGF-β3、cd105、p-ERK 1/2、ERK 1/2、PI3K、p-AKT、AKT、PDK1的表达水平。同时检测miR-381-3p水平。结果:HDAC8抑制剂PCI-34051通过调节miR-381-3p及其下游基因TGF-β3的水平,改变哮喘炎症和气道重塑的所有经典组织学和细胞变化。抑制TGF-β3进一步降低ERK、PI3K、AKT和PDK1的激活。结论:在小鼠模型中,HDAC8抑制剂PCI-34051能全面控制哮喘变化,包括炎症和气道重塑。
{"title":"Selective HDAC8 inhibition by PCI-34051 attenuates inflammation and airway remodeling in asthma <i>via</i> miR-381-3p-TGFβ3 axis.","authors":"Shiyao Bai, Xinming Su, Delei Kong, Chenye Feng, Xiaochun Zhang, Ying Pan, Jieyu Zhao, Jiamin Sun, Wenyang Li","doi":"10.1515/jtim-2023-0135","DOIUrl":"10.1515/jtim-2023-0135","url":null,"abstract":"<p><strong>Background and objectives: </strong>Histone deacetylase (HDAC) families regulate various physical processes and the development of several diseases. The role of HDACs in asthma development and progression worths further investigation. This study aims to evaluate the effect of HDACs in a mouse model of asthma.</p><p><strong>Methods: </strong>HDAC8 selective inhibitor PCI-34051 was administered to a mouse model of ovalbumin-sensitized and challenged asthma. Airway responsiveness, serum cytokines, histological changes of the airway, and expression levels of α-SMA, β-actin, VEGFR, VEGF, GAPDH, HDAC8, TGF-β3, CD 105, p-ERK 1/2, ERK 1/2, PI3K, p-AKT, AKT, and PDK1 were evaluated. The miR-381-3p level was also measured.</p><p><strong>Results: </strong>All classic histologic and cellular changes of asthma in inflammation and airway remodeling were altered by HDAC8 inhibitor PCI-34051 via regulation of the miR-381-3p level and its downstream gene, TGF-β3. Inhibition of TGF-β3 further reduced the activation of ERK, PI3K, AKT, and PDK1.</p><p><strong>Conclusion: </strong>In a mouse model, HDAC8 inhibitor PCI-34051 exhibits comprehensive control of asthmatic changes, including inflammation and airway remodeling.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 6","pages":"592-601"},"PeriodicalIF":4.7,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to "WWP2 protects against sepsis-induced cardiac injury through inhibiting cardiomyocyte ferroptosis". 对 "WWP2 通过抑制心肌细胞铁蛋白沉积防止脓毒症诱发的心脏损伤 "的更正
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI: 10.1515/jtim-2024-0024
Zhi Li, Boquan Wu, Jie Chen, Ning Ye, Rui Ma, Chunyu Song, Yingxian Sun, Xingang Zhang, Guozhe Sun

[This corrects the article DOI: 10.2478/jtim-2024-0004.].

[This corrects the article DOI: 10.2478/jtim-2024-0004.].
{"title":"Erratum to \"WWP2 protects against sepsis-induced cardiac injury through inhibiting cardiomyocyte ferroptosis\".","authors":"Zhi Li, Boquan Wu, Jie Chen, Ning Ye, Rui Ma, Chunyu Song, Yingxian Sun, Xingang Zhang, Guozhe Sun","doi":"10.1515/jtim-2024-0024","DOIUrl":"https://doi.org/10.1515/jtim-2024-0024","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.2478/jtim-2024-0004.].</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 5","pages":"530"},"PeriodicalIF":4.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated untargeted/targeted metabolomics identifies a putative oxylipin signature in patients with atrial fibrillation and coronary heart disease. 综合非靶向/靶向代谢组学确定了心房颤动和冠心病患者的推定氧脂特征。
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI: 10.1515/jtim-2023-0141
Lei Li, Yingyuan Lu, Zhiyong Du, Meng Fang, Ying Wei, Wenxin Zhang, Yisheng Xu, Jiaxu Sun, Xiangrui Zeng, Guomin Hu, Lingli Wang, Yong Jiang, Shuwang Liu, Yida Tang, Haiyi Yu, Pengfei Tu, Xiaoyu Guo

Background and objective: Atrial fibrillation (AF) and coronary heart disease (CHD) are closely related to metabolic dysregulation. However, the metabolic characteristics of AF patients with concomitant CHD remain unclear. The aims of this study were to elucidate the metabolic profiles of patients with AF and CHD to seek new therapeutic targets and related factors of AF combined with CHD.

Methods: Untargeted metabolomics and targeted oxylipins profiling were performed to characterize the serum metabolome landscape of patients with AF, CHD, and AF comorbid CHD.

Results: The serum metabolic fingerprints of patients with AF comorbid CHD were significantly differentiated from normal controls (NC) and individuals with AF or CHD alone, and the differentiated metabolites dominated by a variety of lipid alterations in the phospholipid and fatty acid metabolism. Furthermore, the targeted profiles of oxylipins demonstrated that the levels of arachidonic acid derivatives including prostaglandins, leukotrienes, hydroxy-docosahexaenoic acids, hydroxy-eicostetraenoic acids and hydroxy-eicosatrienoic acids in patients with AF and CHD were significantly different from those in the NC, AF, and CHD groups. Several prostaglandins were positively associated with echocardiographic indicators of myocardial remodeling.

Conclusions: This study updates metabolic insights of AF and CHD and provides potential therapeutic targets for preventing or treating AF comorbid CHD.

背景和目的:心房颤动(AF)和冠心病(CHD)与代谢失调密切相关。然而,伴有冠心病的心房颤动患者的代谢特征仍不清楚。本研究旨在阐明心房颤动和冠心病患者的代谢特征,以寻找心房颤动合并冠心病的新治疗靶点和相关因素:方法:对房颤、冠心病和房颤合并冠心病患者的血清代谢组进行非靶向代谢组学分析和靶向氧脂分析:结果:心房颤动合并冠心病患者的血清代谢指纹与正常对照组(NC)和单纯心房颤动或冠心病患者的血清代谢指纹有明显差异,差异代谢物以磷脂和脂肪酸代谢中的各种脂质改变为主。此外,氧脂的靶向图谱显示,心房颤动和冠心病患者的花生四烯酸衍生物(包括前列腺素、白三烯、羟基二十二碳六烯酸、羟基二十碳四烯酸和羟基二十碳三烯酸)水平与正常心房颤动组、心房颤动组和冠心病组有显著差异。几种前列腺素与心肌重塑的超声心动图指标呈正相关:本研究更新了对房颤和冠心病代谢的认识,为预防或治疗房颤合并冠心病提供了潜在的治疗目标。
{"title":"Integrated untargeted/targeted metabolomics identifies a putative oxylipin signature in patients with atrial fibrillation and coronary heart disease.","authors":"Lei Li, Yingyuan Lu, Zhiyong Du, Meng Fang, Ying Wei, Wenxin Zhang, Yisheng Xu, Jiaxu Sun, Xiangrui Zeng, Guomin Hu, Lingli Wang, Yong Jiang, Shuwang Liu, Yida Tang, Haiyi Yu, Pengfei Tu, Xiaoyu Guo","doi":"10.1515/jtim-2023-0141","DOIUrl":"https://doi.org/10.1515/jtim-2023-0141","url":null,"abstract":"<p><strong>Background and objective: </strong>Atrial fibrillation (AF) and coronary heart disease (CHD) are closely related to metabolic dysregulation. However, the metabolic characteristics of AF patients with concomitant CHD remain unclear. The aims of this study were to elucidate the metabolic profiles of patients with AF and CHD to seek new therapeutic targets and related factors of AF combined with CHD.</p><p><strong>Methods: </strong>Untargeted metabolomics and targeted oxylipins profiling were performed to characterize the serum metabolome landscape of patients with AF, CHD, and AF comorbid CHD.</p><p><strong>Results: </strong>The serum metabolic fingerprints of patients with AF comorbid CHD were significantly differentiated from normal controls (NC) and individuals with AF or CHD alone, and the differentiated metabolites dominated by a variety of lipid alterations in the phospholipid and fatty acid metabolism. Furthermore, the targeted profiles of oxylipins demonstrated that the levels of arachidonic acid derivatives including prostaglandins, leukotrienes, hydroxy-docosahexaenoic acids, hydroxy-eicostetraenoic acids and hydroxy-eicosatrienoic acids in patients with AF and CHD were significantly different from those in the NC, AF, and CHD groups. Several prostaglandins were positively associated with echocardiographic indicators of myocardial remodeling.</p><p><strong>Conclusions: </strong>This study updates metabolic insights of AF and CHD and provides potential therapeutic targets for preventing or treating AF comorbid CHD.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 5","pages":"495-509"},"PeriodicalIF":4.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic prediction of m6A and ferroptosis-associated lncRNAs in liver hepatocellular carcinoma. 肝脏肝细胞癌中与 m6A 和铁突变相关的 lncRNA 的预后预测
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI: 10.1515/jtim-2024-0023
Yuchen Gao, Jingxiao Li, Mingyue Ma, Wenting Fu, Lin Ma, Yi Sui, Yu Wang
{"title":"Prognostic prediction of m6A and ferroptosis-associated lncRNAs in liver hepatocellular carcinoma.","authors":"Yuchen Gao, Jingxiao Li, Mingyue Ma, Wenting Fu, Lin Ma, Yi Sui, Yu Wang","doi":"10.1515/jtim-2024-0023","DOIUrl":"https://doi.org/10.1515/jtim-2024-0023","url":null,"abstract":"","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 5","pages":"526-529"},"PeriodicalIF":4.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows. 肺腺癌的组织学转化:机制和治疗窗口的启示。
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI: 10.1515/jtim-2024-0019
Nuopei Tan, Yan Li, Jianming Ying, Wanqing Chen

Histological transformation from lung adenocarcinoma (ADC) to small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC), squamous cell carcinoma (SCC), and sarcomatoid carcinoma (PSC) after targeted therapies is recognized as a mechanism of resistance in ADC treatments. Patients with transformed lung cancer typically experience a poor prognosis and short survival time. However, effective treatment options for these patients are currently lacking. Therefore, understanding the mechanisms underlying histological transformation is crucial for the development of effective therapies. Hypotheses including intratumoral heterogeneity, cancer stem cells, and alteration of suppressor genes have been proposed to explain the mechanism of histological transformation. In this review, we provide a comprehensive overview of the known molecular features and signaling pathways of transformed tumors, and summarized potential therapies based on previous findings.

在接受靶向治疗后,肺腺癌(ADC)向小细胞肺癌(SCLC)、大细胞神经内分泌癌(LCNEC)、鳞状细胞癌(SCC)和肉瘤样癌(PSC)的组织学转化被认为是 ADC 治疗的一种耐药机制。转化型肺癌患者通常预后较差,生存时间较短。然而,目前还缺乏针对这些患者的有效治疗方案。因此,了解组织学转化的内在机制对于开发有效疗法至关重要。有人提出了包括瘤内异质性、癌症干细胞和抑制基因改变等假说来解释组织学转化的机制。在这篇综述中,我们全面概述了转化肿瘤的已知分子特征和信号通路,并根据以往的研究结果总结了潜在的疗法。
{"title":"Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows.","authors":"Nuopei Tan, Yan Li, Jianming Ying, Wanqing Chen","doi":"10.1515/jtim-2024-0019","DOIUrl":"https://doi.org/10.1515/jtim-2024-0019","url":null,"abstract":"<p><p>Histological transformation from lung adenocarcinoma (ADC) to small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC), squamous cell carcinoma (SCC), and sarcomatoid carcinoma (PSC) after targeted therapies is recognized as a mechanism of resistance in ADC treatments. Patients with transformed lung cancer typically experience a poor prognosis and short survival time. However, effective treatment options for these patients are currently lacking. Therefore, understanding the mechanisms underlying histological transformation is crucial for the development of effective therapies. Hypotheses including intratumoral heterogeneity, cancer stem cells, and alteration of suppressor genes have been proposed to explain the mechanism of histological transformation. In this review, we provide a comprehensive overview of the known molecular features and signaling pathways of transformed tumors, and summarized potential therapies based on previous findings.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 5","pages":"452-465"},"PeriodicalIF":4.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exosomes derived from Umbilical cord mesenchymal stem cell promote hair regrowth in C57BL6 mice through upregulation of the RAS/ERK signaling pathway. 脐带间充质干细胞提取的外泌体通过上调RAS/ERK信号通路促进C57BL6小鼠毛发再生。
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI: 10.1515/jtim-2024-0012
Yongcui Mao, Pinyan Liu, Jiayun Wei, Ye Xie, Qiuxia Zheng, Xuekai Hu, Jia Yao, Wenbo Meng

Background and objectives: Androgenetic alopecia is one of the common types of hair loss and has become a medical and social problem due to its increasingly young onset. Existing therapies, although effective, have serious side effects and therefore better treatments need to be sought. The aim of this study was to evaluate the efficacy of umbilical cord mesenchymal stem cell-derived exosomes in the treatment of androgenetic alopecia and to investigate the mechanism of exosome regulation of hair growth.

Methods: First, we randomly divided 20 C57BL/6J mice into blank group, model group, positive control group and exosomal hydrogel group, and mice were treated with hair removal on the back. The mice were injected intraperitoneally with dihydrotestosterone solution except for the blank group. At the end of the experiment, new hairs were collected and the differences in length, diameter and number of hair follicles were compared among the groups; the histopathological changes of hair follicles were observed by HE staining; the expression of androgen receptor mRNA and protein in skin tissues were compared; and the skin tissues were analyzed by real-time PCR, western blotting, immunofluorescence staining and transcriptome sequencing. Finally, the results of transcriptome sequencing experiments were verified by real-time PCR, western blotting and other techniques for the corresponding genes and proteins.

Results: Compared with the blank group, mice in the model group had shorter hair length and reduced hair diameter, and pathological observation showed that the total number of hair follicles was significantly reduced and the hair follicles were miniaturized; compared with the model group, mice in the positive control and exosome groups had longer hair length, larger hair diameter and more hair follicles; the androgen receptor mRNA content and protein expression in the skin tissue of mice in the model group were significantly higher than those in the blank group, and the protein expression in the exosome gel group was lower than that in the model group. Similarly, compared with the model group, the expression of stemness-related proteins K15 and CD200 in the skin tissues of mice in the exosome group increased, and the expression of PCNA, a protein related to cell proliferation, increased. The KEGG data showed that the differential genes were mainly enriched in the RAS/ERK pathway.

Conclusions: In this study, we demonstrated the therapeutic effect of umbilical cord MSC-derived exosomes on androgenetic alopecia and verified that exosomes regulate hair follicle stem cell stemness through the RAS/ERK pathway to promote hair proliferation and thus hair growth in mice with androgenetic alopecia, providing a potential therapeutic strategy for androgenetic alopecia.

背景和目的:雄激素性脱发是常见的脱发类型之一,由于发病年龄越来越小,已成为一个医学和社会问题。现有疗法虽然有效,但有严重的副作用,因此需要寻求更好的治疗方法。本研究旨在评估脐带间充质干细胞外泌体治疗雄激素性脱发的疗效,并探讨外泌体调控毛发生长的机制:首先,将20只C57BL/6J小鼠随机分为空白组、模型组、阳性对照组和外泌体水凝胶组,对小鼠背部进行脱毛处理。除空白组外,小鼠均腹腔注射双氢睾酮溶液。实验结束后,收集新毛,比较各组毛囊长度、直径和数量的差异;用 HE 染色法观察毛囊的组织病理学变化;比较雄激素受体 mRNA 和蛋白在皮肤组织中的表达;并对皮肤组织进行实时 PCR、Western 印迹、免疫荧光染色和转录组测序分析。最后,通过实时 PCR、Western 印迹等技术对转录组测序实验的结果进行相应基因和蛋白质的验证:结果:与空白对照组相比,模型组小鼠的毛发长度缩短,毛发直径减小,病理观察显示毛囊总数明显减少,毛囊小型化;与模型组相比,阳性对照组和外泌体组小鼠的毛发长度延长,毛发直径增大,毛囊增多;模型组小鼠皮肤组织中雄激素受体 mRNA 含量和蛋白表达量明显高于空白组,而外泌体凝胶组的蛋白表达量低于模型组。同样,与模型组相比,外泌体组小鼠皮肤组织中干性相关蛋白 K15 和 CD200 的表达量增加,与细胞增殖相关的蛋白 PCNA 的表达量增加。KEGG数据显示,差异基因主要富集于RAS/ERK通路:本研究证明了脐带间充质干细胞衍生外泌体对雄激素性脱发的治疗作用,并验证了外泌体通过RAS/ERK通路调节毛囊干细胞干性,促进毛发增殖,从而促进雄激素性脱发小鼠的毛发生长,为雄激素性脱发提供了一种潜在的治疗策略。
{"title":"Exosomes derived from Umbilical cord mesenchymal stem cell promote hair regrowth in C57BL6 mice through upregulation of the RAS/ERK signaling pathway.","authors":"Yongcui Mao, Pinyan Liu, Jiayun Wei, Ye Xie, Qiuxia Zheng, Xuekai Hu, Jia Yao, Wenbo Meng","doi":"10.1515/jtim-2024-0012","DOIUrl":"https://doi.org/10.1515/jtim-2024-0012","url":null,"abstract":"<p><strong>Background and objectives: </strong>Androgenetic alopecia is one of the common types of hair loss and has become a medical and social problem due to its increasingly young onset. Existing therapies, although effective, have serious side effects and therefore better treatments need to be sought. The aim of this study was to evaluate the efficacy of umbilical cord mesenchymal stem cell-derived exosomes in the treatment of androgenetic alopecia and to investigate the mechanism of exosome regulation of hair growth.</p><p><strong>Methods: </strong>First, we randomly divided 20 C57BL/6J mice into blank group, model group, positive control group and exosomal hydrogel group, and mice were treated with hair removal on the back. The mice were injected intraperitoneally with dihydrotestosterone solution except for the blank group. At the end of the experiment, new hairs were collected and the differences in length, diameter and number of hair follicles were compared among the groups; the histopathological changes of hair follicles were observed by HE staining; the expression of androgen receptor mRNA and protein in skin tissues were compared; and the skin tissues were analyzed by real-time PCR, western blotting, immunofluorescence staining and transcriptome sequencing. Finally, the results of transcriptome sequencing experiments were verified by real-time PCR, western blotting and other techniques for the corresponding genes and proteins.</p><p><strong>Results: </strong>Compared with the blank group, mice in the model group had shorter hair length and reduced hair diameter, and pathological observation showed that the total number of hair follicles was significantly reduced and the hair follicles were miniaturized; compared with the model group, mice in the positive control and exosome groups had longer hair length, larger hair diameter and more hair follicles; the androgen receptor mRNA content and protein expression in the skin tissue of mice in the model group were significantly higher than those in the blank group, and the protein expression in the exosome gel group was lower than that in the model group. Similarly, compared with the model group, the expression of stemness-related proteins K15 and CD200 in the skin tissues of mice in the exosome group increased, and the expression of PCNA, a protein related to cell proliferation, increased. The KEGG data showed that the differential genes were mainly enriched in the RAS/ERK pathway.</p><p><strong>Conclusions: </strong>In this study, we demonstrated the therapeutic effect of umbilical cord MSC-derived exosomes on androgenetic alopecia and verified that exosomes regulate hair follicle stem cell stemness through the RAS/ERK pathway to promote hair proliferation and thus hair growth in mice with androgenetic alopecia, providing a potential therapeutic strategy for androgenetic alopecia.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 5","pages":"478-494"},"PeriodicalIF":4.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastroesophageal reflux disease influences blood pressure components, lipid profile and cardiovascular diseases: Evidence from a Mendelian randomization study. 胃食管反流病影响血压成分、血脂和心血管疾病:孟德尔随机研究的证据。
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI: 10.1515/jtim-2024-0017
Qiang Wu, Changjing He, Wanzhong Huang, Chaoqun Song, Xin Hao, Qing Zeng, Dazhi Lan, Qiang Su

Background: Gastroesophageal reflux disease (GERD) is a prevalent gastrointestinal disorder associated with a range of cardiovascular and metabolic complications. However, the relationship between GERD and blood pressure components, lipid profile, and cardiovascular diseases remains unclear.

Methods: Leveraging genetic variants associated with GERD as instrumental variables, we performed this Mendelian randomization (MR) analyses. Blood pressure components, lipid profile parameters, as well as cardiovascular diseases were considered as outcomes. Furthermore, we conducted reverse MR analysis to explore the association of these factors with the risk of GERD.

Results: Our MR analysis discovered a potential causal influence of GERD on blood pressure components, with genetically predicted GERD positively associated with systolic blood pressure (β = 0.053, P = 0.036), diastolic blood pressure (β = 0.100, P < 0.001), and mean arterial pressure (β = 0.106, P < 0.001). Additionally, genetically predicted GERD showed a significant impact on lipid profile, leading to increased genetically predicted levels of low-density lipoprotein (LDL) cholesterol (β = 0.093, P < 0.001), and triglycerides (β = 0.153, P < 0.001), while having a negative effect on high-density lipoprotein (HDL) cholesterol (β = -0.115, P = 0.002). Furthermore, our study indicated a noteworthy causal association between genetically predicted GERD and increased risk of myocardial infarction [odds ratio (OR) = 1.272, P = 0.019)] and hypertension (OR = 1.357, P < 0.001). No significant association was found between GERD and pulse pressure, total cholesterol, heart failure, and atrial fibrillation (P > 0.05). Reverse MR analysis indicates that blood pressure components, lipid profile, and cardiovascular diseases do not lead to an increased risk of GERD (all P > 0.05). Furthermore, mediation MR analysis reveals that LDL cholesterol (proportion mediated: 19.99%, 95% CI: 4.49% to 35.50%), HDL cholesterol (proportion mediated: 11.71%, 95% CI: 5.23% to 18.19%), and hypertension (proportion mediated: 35.09%, 95% CI: 24.66% to 45.53%) mediated the effect of GERD on myocardial infarction, while other factors did not participate in this pathway.

Conclusions: This MR study provides evidence supporting a causal relationship between GERD and alterations in blood pressure components, lipid profile, and increased risk of cardiovascular diseases.

背景:胃食管反流病(GERD胃食管反流病(GERD)是一种常见的胃肠道疾病,与一系列心血管和代谢并发症有关。然而,胃食管反流病与血压成分、血脂和心血管疾病之间的关系仍不清楚:利用与胃食管反流病相关的基因变异作为工具变量,我们进行了孟德尔随机化(MR)分析。我们利用与胃食管反流病相关的基因变异作为工具变量,进行了孟德尔随机化(Mendelian randomization,MR)分析,将血压成分、血脂曲线参数以及心血管疾病作为结果。此外,我们还进行了反向 MR 分析,以探讨这些因素与胃食管反流病风险的关联:我们的磁共振分析发现胃食管反流病对血压成分有潜在的因果影响,遗传预测的胃食管反流病与收缩压(β = 0.053,P = 0.036)、舒张压(β = 0.100,P < 0.001)和平均动脉压(β = 0.106,P < 0.001)呈正相关。此外,遗传预测的胃食管反流病对血脂有显著影响,导致遗传预测的低密度脂蛋白胆固醇(LDL)(β = 0.093,P < 0.001)和甘油三酯(β = 0.153,P < 0.001)水平升高,同时对高密度脂蛋白胆固醇(HDL)(β = -0.115,P = 0.002)有负面影响。此外,我们的研究表明,遗传预测的胃食管反流病与心肌梗死风险增加[几率比(OR)= 1.272,P = 0.019]和高血压(OR = 1.357,P < 0.001)之间存在值得注意的因果关系。)胃食管反流病与脉压、总胆固醇、心力衰竭和心房颤动之间无明显关联(P > 0.05)。反向 MR 分析表明,血压成分、血脂状况和心血管疾病不会导致胃食管反流病的风险增加(所有 P > 0.05)。此外,中介MR分析显示,低密度脂蛋白胆固醇(中介比例:19.99%,95% CI:4.49%至35.50%)、高密度脂蛋白胆固醇(中介比例:11.71%,95% CI:5.23%至18.19%)和高血压(中介比例:35.09%,95% CI:24.66%至45.53%)是胃食管反流病对心肌梗死影响的中介,而其他因素并未参与这一途径:这项磁共振研究为胃食管反流病与血压成分、血脂状况的改变以及心血管疾病风险的增加之间的因果关系提供了证据。
{"title":"Gastroesophageal reflux disease influences blood pressure components, lipid profile and cardiovascular diseases: Evidence from a Mendelian randomization study.","authors":"Qiang Wu, Changjing He, Wanzhong Huang, Chaoqun Song, Xin Hao, Qing Zeng, Dazhi Lan, Qiang Su","doi":"10.1515/jtim-2024-0017","DOIUrl":"https://doi.org/10.1515/jtim-2024-0017","url":null,"abstract":"<p><strong>Background: </strong>Gastroesophageal reflux disease (GERD) is a prevalent gastrointestinal disorder associated with a range of cardiovascular and metabolic complications. However, the relationship between GERD and blood pressure components, lipid profile, and cardiovascular diseases remains unclear.</p><p><strong>Methods: </strong>Leveraging genetic variants associated with GERD as instrumental variables, we performed this Mendelian randomization (MR) analyses. Blood pressure components, lipid profile parameters, as well as cardiovascular diseases were considered as outcomes. Furthermore, we conducted reverse MR analysis to explore the association of these factors with the risk of GERD.</p><p><strong>Results: </strong>Our MR analysis discovered a potential causal influence of GERD on blood pressure components, with genetically predicted GERD positively associated with systolic blood pressure (β = 0.053, <i>P</i> = 0.036), diastolic blood pressure (β = 0.100, <i>P</i> < 0.001), and mean arterial pressure (β = 0.106, <i>P</i> < 0.001). Additionally, genetically predicted GERD showed a significant impact on lipid profile, leading to increased genetically predicted levels of low-density lipoprotein (LDL) cholesterol (β = 0.093, <i>P</i> < 0.001), and triglycerides (β = 0.153, <i>P</i> < 0.001), while having a negative effect on high-density lipoprotein (HDL) cholesterol (β = -0.115, <i>P</i> = 0.002). Furthermore, our study indicated a noteworthy causal association between genetically predicted GERD and increased risk of myocardial infarction [odds ratio (OR) = 1.272, <i>P</i> = 0.019)] and hypertension (OR = 1.357, <i>P</i> < 0.001). No significant association was found between GERD and pulse pressure, total cholesterol, heart failure, and atrial fibrillation (<i>P</i> > 0.05). Reverse MR analysis indicates that blood pressure components, lipid profile, and cardiovascular diseases do not lead to an increased risk of GERD (all <i>P</i> > 0.05). Furthermore, mediation MR analysis reveals that LDL cholesterol (proportion mediated: 19.99%, 95% CI: 4.49% to 35.50%), HDL cholesterol (proportion mediated: 11.71%, 95% CI: 5.23% to 18.19%), and hypertension (proportion mediated: 35.09%, 95% CI: 24.66% to 45.53%) mediated the effect of GERD on myocardial infarction, while other factors did not participate in this pathway.</p><p><strong>Conclusions: </strong>This MR study provides evidence supporting a causal relationship between GERD and alterations in blood pressure components, lipid profile, and increased risk of cardiovascular diseases.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 5","pages":"510-525"},"PeriodicalIF":4.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial. 伊奈他单抗注射液联合长春瑞滨每周或每三周治疗 HER2 阳性转移性乳腺癌:多中心、随机、II 期临床试验。
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI: 10.1515/jtim-2024-0022
Xiying Shao, Ning Xie, Zhanhong Chen, Xinshuai Wang, Wenming Cao, Yabing Zheng, Hua Yang, Jian Huang, Shaoping Chen, Lu Gan, Xiuli Yang, Yuru Chen, Quchang Ouyang, Xiaojia Wang

Objective: We aimed to investigate the pharmacokinetics, safety, efficacy, and immunogenicity of different dosing regimens (weekly and every three weeks) of inetetamab in combination with vinorelbine in human epidermal growth factor receptor 2 (HER2)+ patients with metastatic breast cancer who had received one or more chemotherapy regimens.

Methods: HER2+ patients with metastatic breast cancer who had received one or more chemotherapy regimens were included. Eligible patients received inetetamab administered weekly or every three weeks in combination with vinorelbine injection chemotherapy. Pharmacokinetics, safety, efficacy, and immunogenicity were compared between the groups.

Results: Sixty HER2+ patients were randomized into a single-week administration group ( n = 29) and a three-week administration group ( n = 31). After the final dose in the single-week administration group and the three-week administration group, the mean Cmax values were 79.773 μg/mL and 146.083 μg/mL; the mean Cmin values were 30.227 μg/mL and 11.926 μg/mL; the mean AUCtau values were 7328.443 μg·h/mL and 22647.101 μg·h/mL; and the mean Cav values were 43.622 μg/ mL and 44.935 μg/mL, respectively. The best overall response (BOR) rates at 24 weeks and unconfirmed BOR rates at 24 weeks were both 40.7% in the single-week dosing group and 40.7% in the three-week dosing group, and the 24-week confirmed disease control rates (DCRs) were 88.9% and 81.5%, respectively. The incidence of adverse events (AEs) was generally consistent across all levels.

Conclusion: There were slight differences in the mean Cmax, Cmin, AUCtau and Cav between the three-week dosing group and the single-week dosing group, and the mean steady-state concentrations of Cav were comparable; however, there were no differences in efficacy, safety or immunogenicity between the two groups.

研究目的方法:纳入接受过一种或多种化疗方案的 HER2+ 转移性乳腺癌患者。符合条件的患者每周或每三周接受一次伊奈他单抗与长春瑞滨注射液联合化疗。比较两组患者的药代动力学、安全性、有效性和免疫原性:60例HER2+患者被随机分为单周用药组(29例)和三周用药组(31例)。单周给药组和三周给药组最后一次给药后,平均 Cmax 值分别为 79.773 μg/mL 和 146.083 μg/mL;平均 Cmin 值分别为 30.227 μg/mL和11.926 μg/mL;平均AUCtau值分别为7328.443 μg-h/mL和22647.101 μg-h/mL;平均Cav值分别为43.622 μg/mL和44.935 μg/mL。单周给药组和三周给药组的24周最佳总反应率(BOR)和24周未确诊总反应率(BOR)均为40.7%,24周确诊疾病控制率(DCR)分别为88.9%和81.5%。所有级别的不良事件(AEs)发生率基本一致:结论:三周给药组与单周给药组的平均Cmax、Cmin、AUCtau和Cav略有不同,Cav的平均稳态浓度相当;但两组在疗效、安全性和免疫原性方面没有差异。
{"title":"Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial.","authors":"Xiying Shao, Ning Xie, Zhanhong Chen, Xinshuai Wang, Wenming Cao, Yabing Zheng, Hua Yang, Jian Huang, Shaoping Chen, Lu Gan, Xiuli Yang, Yuru Chen, Quchang Ouyang, Xiaojia Wang","doi":"10.1515/jtim-2024-0022","DOIUrl":"https://doi.org/10.1515/jtim-2024-0022","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to investigate the pharmacokinetics, safety, efficacy, and immunogenicity of different dosing regimens (weekly and every three weeks) of inetetamab in combination with vinorelbine in human epidermal growth factor receptor 2 (HER2)+ patients with metastatic breast cancer who had received one or more chemotherapy regimens.</p><p><strong>Methods: </strong>HER2+ patients with metastatic breast cancer who had received one or more chemotherapy regimens were included. Eligible patients received inetetamab administered weekly or every three weeks in combination with vinorelbine injection chemotherapy. Pharmacokinetics, safety, efficacy, and immunogenicity were compared between the groups.</p><p><strong>Results: </strong>Sixty HER2+ patients were randomized into a single-week administration group ( <i>n</i> = 29) and a three-week administration group ( <i>n</i> = 31). After the final dose in the single-week administration group and the three-week administration group, the mean C<sub>max</sub> values were 79.773 μg/mL and 146.083 μg/mL; the mean C<sub>min</sub> values were 30.227 μg/mL and 11.926 μg/mL; the mean AUC<sub>tau</sub> values were 7328.443 μg·h/mL and 22647.101 μg·h/mL; and the mean C<sub>av</sub> values were 43.622 μg/ mL and 44.935 μg/mL, respectively. The best overall response (BOR) rates at 24 weeks and unconfirmed BOR rates at 24 weeks were both 40.7% in the single-week dosing group and 40.7% in the three-week dosing group, and the 24-week confirmed disease control rates (DCRs) were 88.9% and 81.5%, respectively. The incidence of adverse events (AEs) was generally consistent across all levels.</p><p><strong>Conclusion: </strong>There were slight differences in the mean C<sub>max</sub>, C<sub>min</sub>, AUC<sub>tau</sub> and C<sub>av</sub> between the three-week dosing group and the single-week dosing group, and the mean steady-state concentrations of C<sub>av</sub> were comparable; however, there were no differences in efficacy, safety or immunogenicity between the two groups.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 5","pages":"466-477"},"PeriodicalIF":4.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Actin-related protein 2/3 complex subunit 1B promotes ovarian cancer progression by regulating the AKT/PI3K/mTOR signaling pathway. 肌动蛋白相关蛋白 2/3 复合物亚基 1B 通过调节 AKT/PI3K/mTOR 信号通路促进卵巢癌的进展。
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01 eCollection Date: 2024-09-01 DOI: 10.2478/jtim-2024-0025
Miao Ke, Huimin Zhu, Yu Lin, Ying Zhang, Tao Tang, Yuhao Xie, Zhe-Sheng Chen, Xiaoyu Wang, Yuan Shen

Background and objectives: Actin-related protein 2/3 complex subunit 1B (ARPC1B) is an essential subunit of the actin-related protein 2/3 (Arp2/3) complex. While there have been numerous research reports on Arp2/3 in relation to tumors, there needs to be more research on ARPC1B and its role in tumors, particularly at the pan-cancer level.

Methods: Utilizing data from the cancer genome atlas (TCGA) and genotype-tissue expression (GTEx) databases, we analyzed ARPC1B expression differences in normal, tumor, and adjacent tissues, investigating its correlation with prognosis and clinical stages in various cancers. We conducted gene enrichment analysis and explored ARPC1B's connection to the tumor immune microenvironment and its impact on anti-tumor drug resistance. In addition, in vivo and in vitro experiments have also been carried out to find the mechanism of ARPC1B on ovarian cancer (OV) proliferation and invasion.

Results: ARPC1B was highly expressed in 33 tumor types, suggesting its role as a tumor-promoting factor. Its expression correlated with poor prognosis and served as a clinical staging marker in over 10 tumor types. ARPC1B is implicated in various biological processes and signaling pathways, uniquely associated with tumor immunity, indicating immunosuppressive conditions in high-expression cases. High ARPC1B expression was linked to resistance to six anti-tumor drugs. Further experiments showed that ARPC1B can affect the proliferation, apoptosis, migration, and invasion of OV cells through the AKT/PI3K/mTOR pathway.

Conclusion: ARPC1B is a biomarker for immune suppression, prognosis, clinical staging, and drug resistance, providing new insights for cancer therapeutics.

背景和目的:肌动蛋白相关蛋白2/3复合体亚基1B(ARPC1B)是肌动蛋白相关蛋白2/3(Arp2/3)复合体的一个重要亚基。虽然已有大量关于 Arp2/3 与肿瘤关系的研究报告,但还需要更多关于 ARPC1B 及其在肿瘤中作用的研究,特别是在泛癌症层面:利用癌症基因组图谱(TCGA)和基因型-组织表达(GTEx)数据库的数据,我们分析了ARPC1B在正常组织、肿瘤组织和邻近组织中的表达差异,研究了它与各种癌症的预后和临床分期的相关性。我们进行了基因富集分析,探讨了 ARPC1B 与肿瘤免疫微环境的联系及其对抗肿瘤药物耐药性的影响。此外,我们还进行了体内和体外实验,以寻找 ARPC1B 对卵巢癌(OV)增殖和侵袭的影响机制:结果:ARPC1B 在 33 种肿瘤类型中高表达,表明它是一种肿瘤促进因子。ARPC1B的表达与预后不良相关,可作为10多种肿瘤类型的临床分期标志物。ARPC1B 与多种生物过程和信号通路有关,与肿瘤免疫独特相关,表明在高表达病例中存在免疫抑制情况。ARPC1B 的高表达与六种抗肿瘤药物的耐药性有关。进一步的实验表明,ARPC1B可通过AKT/PI3K/mTOR通路影响OV细胞的增殖、凋亡、迁移和侵袭:结论:ARPC1B是免疫抑制、预后、临床分期和耐药性的生物标志物,为癌症治疗提供了新的见解。
{"title":"Actin-related protein 2/3 complex subunit 1B promotes ovarian cancer progression by regulating the AKT/PI3K/mTOR signaling pathway.","authors":"Miao Ke, Huimin Zhu, Yu Lin, Ying Zhang, Tao Tang, Yuhao Xie, Zhe-Sheng Chen, Xiaoyu Wang, Yuan Shen","doi":"10.2478/jtim-2024-0025","DOIUrl":"10.2478/jtim-2024-0025","url":null,"abstract":"<p><strong>Background and objectives: </strong>Actin-related protein 2/3 complex subunit 1B (ARPC1B) is an essential subunit of the actin-related protein 2/3 (Arp2/3) complex. While there have been numerous research reports on Arp2/3 in relation to tumors, there needs to be more research on ARPC1B and its role in tumors, particularly at the pan-cancer level.</p><p><strong>Methods: </strong>Utilizing data from the cancer genome atlas (TCGA) and genotype-tissue expression (GTEx) databases, we analyzed ARPC1B expression differences in normal, tumor, and adjacent tissues, investigating its correlation with prognosis and clinical stages in various cancers. We conducted gene enrichment analysis and explored ARPC1B's connection to the tumor immune microenvironment and its impact on anti-tumor drug resistance. In addition, <i>in vivo</i> and <i>in vitro</i> experiments have also been carried out to find the mechanism of ARPC1B on ovarian cancer (OV) proliferation and invasion.</p><p><strong>Results: </strong>ARPC1B was highly expressed in 33 tumor types, suggesting its role as a tumor-promoting factor. Its expression correlated with poor prognosis and served as a clinical staging marker in over 10 tumor types. ARPC1B is implicated in various biological processes and signaling pathways, uniquely associated with tumor immunity, indicating immunosuppressive conditions in high-expression cases. High ARPC1B expression was linked to resistance to six anti-tumor drugs. Further experiments showed that ARPC1B can affect the proliferation, apoptosis, migration, and invasion of OV cells through the AKT/PI3K/mTOR pathway.</p><p><strong>Conclusion: </strong>ARPC1B is a biomarker for immune suppression, prognosis, clinical staging, and drug resistance, providing new insights for cancer therapeutics.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 4","pages":"406-423"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of functional heterogeneity of immune cells and tubular-immune cellular interplay action in diabetic kidney disease. 鉴定糖尿病肾病中免疫细胞的功能异质性和肾小管-免疫细胞的相互作用。
IF 4.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01 eCollection Date: 2024-09-01 DOI: 10.2478/jtim-2023-0130
Yunfeng Bai, Kun Chi, Delong Zhao, Wanjun Shen, Ran Liu, Jing Hao, Guangyan Cai, Xiangmei Chen, Quan Hong

Background: Renal inflammation plays key roles in the pathogenesis of diabetic kidney disease (DKD). Immune cell infiltration is the main pathological feature in the progression of DKD. Sodium glucose cotransporter 2 inhibitor (SGLT2i) were reported to have antiinflammatory effects on DKD. While the heterogeneity and molecular basis of the pathogenesis and treatment with SGLT2i in DKD remains poorly understood.

Methods: To address this question, we performed a single-cell transcriptomics data analysis and cell cross-talk analysis based on the database (GSE181382). The single-cell transcriptome analysis findings were validated using multiplex immunostaining.

Results: A total of 58760 cells are categorized into 25 distinct cell types. A subset of macrophages with anti-inflammatory potential was identified. We found that Ccl3+ (S100a8/a9 high) macrophages with anti-inflammatory and antimicrobial in the pathogenesis of DKD decreased and reversed the dapagliflozin treatment. Besides, dapagliflozin treatment enhanced the accumulation of Pck1+ macrophage, characterized by gluconeogenesis signaling pathway. Cell-cross talk analysis showed the GRN/SORT1 pair and CD74 related signaling pathways were enriched in the interactions between tubular epithelial cells and immune cells.

Conclusions: Our study depicts the heterogeneity of macrophages and clarifies a new possible explanation of dapagliflozin treatment, showing the metabolism shifts toward gluconeogenesis in macrophages, fueling the anti-inflammatory function of M2 macrophages, highlighting the new molecular features and signaling pathways and potential therapeutic targets, which has provided an important reference for the study of immune-related mechanisms in the progression of the disease.

背景:肾脏炎症在糖尿病肾病(DKD)的发病机制中起着关键作用。免疫细胞浸润是糖尿病肾病进展的主要病理特征。据报道,葡萄糖钠共转运体 2 抑制剂(SGLT2i)对 DKD 有抗炎作用。然而,DKD的发病机制和SGLT2i治疗的异质性和分子基础仍不甚明了:为了解决这个问题,我们基于数据库(GSE181382)进行了单细胞转录组学数据分析和细胞交叉对话分析。单细胞转录组分析结果通过多重免疫染色法进行了验证:共有 58760 个细胞被分为 25 种不同的细胞类型。结果:共有 58760 个细胞被分为 25 种不同的细胞类型。我们发现,Ccl3+(S100a8/a9 高)巨噬细胞在 DKD 的发病机制中具有抗炎和抗菌作用,在达帕利洛嗪治疗后减少并逆转。此外,达帕格列净还增强了以糖元生成信号通路为特征的Pck1+巨噬细胞的聚集。细胞交叉对话分析表明,GRN/SORT1对和CD74相关信号通路在肾小管上皮细胞与免疫细胞的相互作用中得到了丰富:我们的研究描绘了巨噬细胞的异质性,阐明了达帕利嗪治疗的一种新的可能解释,显示了巨噬细胞的代谢转向葡萄糖生成,助长了M2巨噬细胞的抗炎功能,突出了新的分子特征和信号通路以及潜在的治疗靶点,为研究疾病进展中的免疫相关机制提供了重要参考。
{"title":"Identification of functional heterogeneity of immune cells and tubular-immune cellular interplay action in diabetic kidney disease.","authors":"Yunfeng Bai, Kun Chi, Delong Zhao, Wanjun Shen, Ran Liu, Jing Hao, Guangyan Cai, Xiangmei Chen, Quan Hong","doi":"10.2478/jtim-2023-0130","DOIUrl":"10.2478/jtim-2023-0130","url":null,"abstract":"<p><strong>Background: </strong>Renal inflammation plays key roles in the pathogenesis of diabetic kidney disease (DKD). Immune cell infiltration is the main pathological feature in the progression of DKD. Sodium glucose cotransporter 2 inhibitor (SGLT2i) were reported to have antiinflammatory effects on DKD. While the heterogeneity and molecular basis of the pathogenesis and treatment with SGLT2i in DKD remains poorly understood.</p><p><strong>Methods: </strong>To address this question, we performed a single-cell transcriptomics data analysis and cell cross-talk analysis based on the database (GSE181382). The single-cell transcriptome analysis findings were validated using multiplex immunostaining.</p><p><strong>Results: </strong>A total of 58760 cells are categorized into 25 distinct cell types. A subset of macrophages with anti-inflammatory potential was identified. We found that Ccl3+ (S100a8/a9 high) macrophages with anti-inflammatory and antimicrobial in the pathogenesis of DKD decreased and reversed the dapagliflozin treatment. Besides, dapagliflozin treatment enhanced the accumulation of Pck1+ macrophage, characterized by gluconeogenesis signaling pathway. Cell-cross talk analysis showed the GRN/SORT1 pair and CD74 related signaling pathways were enriched in the interactions between tubular epithelial cells and immune cells.</p><p><strong>Conclusions: </strong>Our study depicts the heterogeneity of macrophages and clarifies a new possible explanation of dapagliflozin treatment, showing the metabolism shifts toward gluconeogenesis in macrophages, fueling the anti-inflammatory function of M2 macrophages, highlighting the new molecular features and signaling pathways and potential therapeutic targets, which has provided an important reference for the study of immune-related mechanisms in the progression of the disease.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 4","pages":"395-405"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Translational Internal Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1